This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 15 October 2020].World Health Organization (WHO)https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 15 October 2020].Search in Google Scholar
Aletreby WT, Alharthy AM, Faqihi F, Mady AF, Ramadan OE, Huwait BM, et al. Dynamics of SARS CoV-2 outbreak in the Kingdom of Saudi Arabia: A predictive model. Saudi Crit Care J 2020;4:79–83. doi: 10.4103/sccj.sccj_19_20AletrebyWTAlharthyAMFaqihiFMadyAFRamadanOEHuwaitBMDynamics of SARS CoV-2 outbreak in the Kingdom of Saudi Arabia: A predictive model20204798310.4103/sccj.sccj_19_20Open DOISearch in Google Scholar
Mady A, Aletreby W, Abdulrahman B, Lhmdi M, Noor AM, Alqahtani SA, Soliman I, Alharthy A, Karakitsos D, Memish ZA. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. Ann Med Surg (Lond). 2020 Dec;60:417–424. doi: 10.1016/j.amsu.2020.10.061.MadyAAletrebyWAbdulrahmanBLhmdiMNoorAMAlqahtaniSASolimanIAlharthyAKarakitsosDMemishZATocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series2020Dec6041742410.1016/j.amsu.2020.10.061764280833169088Open DOISearch in Google Scholar
Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 May 5:10.1002/jmv.25964. doi: 10.1002/jmv.25964.AlattarRIbrahimTBHShaarSHAbdallaSShukriKDaghfalJNTocilizumab for the treatment of severe coronavirus disease 20192020May510.1002/jmv.25964.10.1002/jmv.25964726759432369191Open DOISearch in Google Scholar
Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 Sep 29;24(1):589. doi: 10.1186/s13054-020-03306-6.MenzellaFFontanaMSalvaraniCMassariMRuggieroPScelfoCEfficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation2020Sep2924158910.1186/s13054-020-03306-6752325832993751Open DOISearch in Google Scholar
Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020. doi: 10.1002/jmv.25948.AzizMFatimaRAssalyRElevated interleukin-6 and severe COVID-19: a meta-analysis202010.1002/jmv.25948726738332343429Open DOISearch in Google Scholar
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. doi: 10.1016/S0140-6736(20)30566-3.ZhouFYuTDuRFanGLiuYLiuZClinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study202039510546210.1016/S0140-6736(20)30566-3727062732171076Open DOISearch in Google Scholar
Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020 Feb 28;15:700–704. doi: 10.1016/j.jtho.2020.02.010TianSHuWNiuLLiuHXuHXiaoS-YPulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer2020Feb281570070410.1016/j.jtho.2020.02.010712886632114094Open DOISearch in Google Scholar
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Jul;92(7):814–818. doi: 10.1002/jmv.25801.LuoPLiuYQiuLLiuXLiuDLiJTocilizumab treatment in COVID-19: A single center experience2020Jul92781481810.1002/jmv.25801726212532253759Open DOISearch in Google Scholar
Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103.LanSHLaiCCHuangHTChangSPLuLCHsuehPRTocilizumab for severe COVID-19: a systematic review and meta-analysis2020Sep56310610310.1016/j.ijantimicag.2020.106103737768532712333Open DOISearch in Google Scholar
US Food and Drug Administration. ACTEMRA (Tocilizumab) Injection, for Intravenous or Subcutaneous Use. US Food and Drug Administration; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdfUS Food and Drug AdministrationUS Food and Drug Administration2017https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdfSearch in Google Scholar
Schoenfeld DA, Hayden D, Oldmixon C, Ringwood N, Thompson BT. Statistical design and analysis issues for the ARDS Clinical Trials Network: the coordinating center perspective. Clin Invest 2012;2:275–289. doi: 10.4155/CLI.12.14SchoenfeldDAHaydenDOldmixonCRingwoodNThompsonBTStatistical design and analysis issues for the ARDS Clinical Trials Network: the coordinating center perspective2012227528910.4155/CLI.12.14Open DOISearch in Google Scholar
Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997 Jul;112(1):164–72. doi: 10.1378/chest.112.1.164.BernardGRWheelerAPAronsMMMorrisPEPazHLRussellJAWrightPEA trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group1997Jul11211647210.1378/chest.112.1.1649228372Open DOISearch in Google Scholar
Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019 Oct 1;200(7):828–836. doi: 10.1164/rccm.201810-2050CP.YehyaNHarhayMOCurleyMAQSchoenfeldDAReederRWReappraisal of ventilator-free days in critical care research2019Oct1200782883610.1164/rccm.201810-2050CP681244731034248Open DOISearch in Google Scholar
Aletreby WT, Mumtaz SA, Al Harthy AM, Shahzad SA, Ramadan OE, Mady AF, et al. Outcome of early mobilization of critically ill patients: A propensity score matching trial. J Intensive & Crit Care. 2018, 4(3); 13. doi: 10.21767/2471-8505.100115AletrebyWTMumtazSAAl HarthyAMShahzadSARamadanOEMadyAFOutcome of early mobilization of critically ill patients: A propensity score matching trial2018431310.21767/2471-8505.100115Open DOISearch in Google Scholar
Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007 Mar 15;165(6):710–8. doi: 10.1093/aje/kwk052.VittinghoffEMcCullochCERelaxing the rule of ten events per variable in logistic and Cox regression2007Mar151656710810.1093/aje/kwk05217182981Open DOISearch in Google Scholar
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509. doi: 10.1080/01621459.1999.10474144FineJPGrayRJA proportional hazards model for the subdistribution of a competing risk19999449650910.1080/01621459.1999.10474144Open DOISearch in Google Scholar
Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo controlled clinical trial of an aerosolized b2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561–568. doi: 10.1164/rccm.201012-2090OC.MatthayMABrowerRGCarsonSDouglasISEisnerMHiteDNational Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo controlled clinical trial of an aerosolized b2-agonist for treatment of acute lung injury201118456156810.1164/rccm.201012-2090OC317554821562125Open DOISearch in Google Scholar
Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J, et al. Lower tidal volume strategy (_3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 2013;39:847–856. doi: 10.1007/s00134-012-2787-6.BeinTWeber-CarstensSGoldmannAMüllerTStaudingerTBrederlauJLower tidal volume strategy (_3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study20133984785610.1007/s00134-012-2787-6362540823306584Open DOISearch in Google Scholar
Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378: 809–818. doi: 10.1056/NEJMoa1705716.AnnaneDRenaultABrun-BuissonCMegarbaneBQuenotJPSiamiSCRICS-TRIGGERSEP NetworkHydrocortisone plus fludrocortisone for adults with septic shock201837880981810.1056/NEJMoa170571629490185Open DOISearch in Google Scholar
Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, Toko L, et al; HNF Hospital Tocilizumab multidisciplinary team. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Aug 13;99:491–495. doi: 10.1016/j.ijid.2020.08.024.KlopfensteinTZayetSLohseASellesPZahraHKadiane-OussouNJTokoLHNF Hospital Tocilizumab multidisciplinary teamImpact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients2020Aug139949149510.1016/j.ijid.2020.08.024742357432798660Open DOISearch in Google Scholar
Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 Oct;2(10):e603–e612. doi: 10.1016/S2665-9913(20)30277-0.BiranNIpAAhnJGoRCWangSMathuraSTocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study2020Oct210e603e61210.1016/S2665-9913(20)30277-0742830332838323Open DOISearch in Google Scholar
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11:ciaa954. doi: 10.1093/cid/ciaa954.SomersECEschenauerGATroostJPGolobJLGandhiTNWangLTocilizumab for treatment of mechanically ventilated patients with COVID-192020Jul11ciaa95410.1093/cid/ciaa954745446232651997Open DOISearch in Google Scholar
Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, Sönnerborg A, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med. 2020 Aug 3:10.1111/joim.13162. doi: 10.1111/joim.13162.EimerJVesterbackaJSvenssonAKStojanovicBWagrellCSönnerborgATocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study2020Aug310.1111/joim.13162.10.1111/joim.13162743641532744399Open DOISearch in Google Scholar
REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Feb 25:NEJMoa2100433. doi: 10.1056/NEJMoa2100433.REMAP-CAP InvestigatorsGordonACMounceyPRAl-BeidhFRowanKMNicholADArabiYMAnnaneDBeaneAvan Bentum-PuijkWBerryLRBhimaniZBontenMJMBradburyCABrunkhorstFMBuzgauAChengACDetryMADuffyEJEstcourtLJFitzgeraldMGoossensHHaniffaRHigginsAMHillsTEHorvatCMLamontagneFLawlerPRLeavisHLLinstrumKMLittonELorenziEMarshallJCMayrFBMcAuleyDFMcGlothlinAMcGuinnessSPMcVerryBJMontgomerySKMorpethSCMurthySOrrKParkeRLParkerJCPatanwalaAEPettiläVRademakerESantosMSSaundersCTSeymourCWShankar-HariMSliglWITurgeonAFTurnerAMvan de VeerdonkFLZarychanskiRGreenCLewisRJAngusDCMcArthurCJBerrySWebbSADerdeLPGInterleukin-6 receptor antagonists in critically ill patients with Covid-192021Feb25NEJMoa2100433.10.1056/NEJMoa2100433795346133631065Open DOISearch in Google Scholar
Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum Á, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sandes AF, Pintão MCT, Castro CG Jr, Santos SV, de Almeida TML, Costa AN, Gebara OCE, de Freitas FGR, Pacheco ES, Machado DJB, Martin J, Conceição FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, de Souza D, Cavalcanti AB, Scheinberg P; Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.VeigaVCPratsJAGGFariasDLCRosaRGDouradoLKZampieriFGMachadoFRLopesRDBerwangerOAzevedoLCPAvezumÁLisboaTCRojasSSOCoelhoJCLeiteRTCarvalhoJCAndradeLECSandesAFPintãoMCTCastroCGJrSantosSVde AlmeidaTMLCostaANGebaraOCEde FreitasFGRPachecoESMachadoDJBMartinJConceiçãoFGSiqueiraSRRDamianiLPIshiharaLMSchneiderDde SouzaDCavalcantiABScheinbergPCoalition covid-19 Brazil VI InvestigatorsEffect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial2021Jan20372n8410.1136/bmj.n84781525133472855Open DOISearch in Google Scholar
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021 Feb 25:NEJMoa2028700. doi: 10.1056/NEJMoa2028700.RosasIOBräuNWatersMGoRCHunterBDBhaganiSSkiestDAzizMSCooperNDouglasISSavicSYoungsteinTDel SorboLCubillo GracianADe La ZerdaDJUstianowskiABaoMDimonacoSGrahamEMatharuBSpotswoodHTsaiLMalhotraATocilizumab in hospitalized patients with severe Covid-19 pneumonia2021Feb25NEJMoa2028700.10.1056/NEJMoa2028700795345933631066Open DOISearch in Google Scholar
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474–e484. doi: 10.1016/S2665-9913(20)30173-9.GuaraldiGMeschiariMCozzi-LepriAMilicJTonelliRMenozziMTocilizumab in patients with severe COVID-19: a retrospective cohort study2020Aug28e474e48410.1016/S2665-9913(20)30173-9731445632835257Open DOISearch in Google Scholar